BG Medicine

In an amended preliminary prospectus for its IPO filed this week, the company noted that it plans to apply more than half the funds raised by the offering to the development of its BGM Galectin-3, AMIPredict, and LipidDx protein biomarker products.

The firm aims to go public at a price of between $13 and $15 per share. It plans to use proceeds to fund the commercial launch of the BGM Galectin-3 test, as well as development of other tests.

BG has filed for an IPO in the US, a few years after withdrawing an effort to float on the Euronext Amsterdam Exchange.

The offering, which would be the company's second try at going public in the past two and a half years, would raise as much as $86 million.

The collaboration is the first cooperative research-and-development agreement between FHS and a commercial partner in the study's 60-year history. It also marks the first time the study has ever used proteomics.


An analysis of UK Biobank data finds hemochromatosis to be more prevalent than thought, according to the BBC.

An analysis finds that female biomedical researchers receive fewer prizes than male ones, and when they do win prizes, they are less prestigious.

In Nature this week: improved genomic analysis using a graph genome reference, tumor mutational burden could predict clinical response to immune checkpoint inhibitors, and more.

Federal researchers tell the Los Angeles Times that the shutdown is causing missed research opportunities as they try to keep their experiments going.